Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized withdrawal study of canakinumab in PAPA syndrome
2021-005754-28Phase 3Active
- Sponsor
- Istituto Giannina Gaslini
- Start
- Jan 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Pyogenic arthritis-pyoderma gangrenosum-acne syndrome (PAPA) comparing Canakinumab maintenance arm with Placebo withdrawal arm (2 arms). Primary endpoint: Proportion of patients without disease flare at week 48. Started Jan 2023; status: active.
02
Drugs
canakinumab
03
Conditions
Pyogenic arthritis-pyoderma gangrenosum-acne syndrome (PAPA)
Beyond the preview
Go deeper on 2021-005754-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-005754-28.